Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Phototoxic drug eruption induc...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer

Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer

Bibliographic Details
Main Authors: Ecem Bostan, Duygu Gulseren, Ozay Gokoz
Format: Article
Language:English
Published: Sociedade Brasileira de Dermatologia 2022-09-01
Series:Anais Brasileiros de Dermatologia
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962022000500695&tlng=en
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962022000500695&tlng=en

Similar Items

  • Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
    by: Nils Degrauwe, et al.
    Published: (2012-06-01)
  • Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
    by: Hari Deshpande, et al.
    Published: (2011-01-01)
  • Vandetanib induced phototoxic reaction progressed to toxic epidermal necrolysis
    by: Busra Demirbag Gul, et al.
    Published: (2022-02-01)
  • Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
    by: Fallahi P, et al.
    Published: (2019-08-01)
  • Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply
    by: Jr, W, et al.
    Published: (2012)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs